Morgan Stanley
CGTX icon

Morgan Stanley’s Cognition Therapeutics CGTX Stock Holding History

Morgan Stanley’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.1K Hold
27,873
– – ﹤0.01% 6655
2026
Q1 		$21.2K Sell
27,873
-65,455
-70% -$76.2K ﹤0.01% 6704
2025
Q4 		$126K Buy
93,328
+60,638
+185% +$98.4K ﹤0.01% 6105
2025
Q3 		$44.1K Buy
32,690
+1,621
+5% +$2.21K ﹤0.01% 6453
2025
Q2 		$9.63K Hold
31,069
– – ﹤0.01% 6867
2025
Q1 		$13.1K Buy
31,069
+14,196
+84% +$8.34K ﹤0.01% 6723
2024
Q4 		$11.8K Buy
16,873
+15,873
+1,587% +$7.85K ﹤0.01% 6744
2024
Q3 		$469 Sell
1,000
-2,000
-67% -$2.06K ﹤0.01% 7307
2024
Q2 		$4.98K Hold
3,000
– – ﹤0.01% 6852
2024
Q1 		$5.46K Sell
3,000
-18,869
-86% -$39K ﹤0.01% 6871
2023
Q4 		$40.5K Hold
21,869
– – ﹤0.01% 6229
2023
Q3 		$31.5K Hold
21,869
– – ﹤0.01% 6334
2023
Q2 		$40K Hold
21,869
– – ﹤0.01% 6307
2023
Q1 		$43.3K Hold
21,869
– – ﹤0.01% 6334
2022
Q4 		$45.9K Hold
21,869
– – ﹤0.01% 6332
2022
Q3 		$42K Hold
21,869
– – ﹤0.01% 6475
2022
Q2 		$46K Buy
+21,869
New +$56.5K ﹤0.01% 6648

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Morgan Stanley's CGTX Position: Q2 2026 in Review

Morgan Stanley held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 27,873 shares worth $32.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6655.

Morgan Stanley first reported a position in CGTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $126K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Morgan Stanley held 27,873 shares of Cognition Therapeutics worth $32.1K as of Q2 2026.
  • Morgan Stanley left its Cognition Therapeutics share count unchanged in Q2 2026.
  • Cognition Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6655 holding.
  • Morgan Stanley first reported a position in Cognition Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Morgan Stanley's Cognition Therapeutics position peaked at $126K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.